Online inquiry

IVTScrip™ mRNA-Anti-IL17RA, AMG827(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2907MR)

This product GTTS-WQ2907MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets IL17RA gene. The antibody can be applied in Crohn's disease (CD) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001289905.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 23765
UniProt ID Q96F46
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL17RA, AMG827(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ2907MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8056MR IVTScrip™ mRNA-Anti-CD33, h2H12ec(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA h2H12ec
GTTS-WQ10703MR IVTScrip™ mRNA-Anti-ALB&IL17A, M-1095(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA M-1095
GTTS-WQ2635MR IVTScrip™ mRNA-Anti-IL2RB, AMG 592(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AMG 592
GTTS-WQ2109MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, Alb-IFNA2 R23 (608)(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA Alb-IFNA2 R23 (608)
GTTS-WQ1113MR IVTScrip™ mRNA-Anti-MAPT, ABBV-8E12(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ABBV-8E12
GTTS-WQ6380MR IVTScrip™ mRNA-Anti-Factor IX substitute, CSL654(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CSL654
GTTS-WQ13671MR IVTScrip™ mRNA-Anti-TNFSF13B, RC18(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA RC18
GTTS-WQ9925MR IVTScrip™ mRNA-Anti-EPHA3, KB-004(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA KB-004
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW